Maraganore admits that RNAi drugs will be limited to diseases where delivery of the drug as well as the costs of making these materials will be acceptable. “Yes, it’s a specialized technology. But it doesn’t have to cure cancer to be of value.” Fair point.
Alnylam Strikes Back: Comments From CEO John Maraganore
#JohnMaraganoreMaraganore, #SpecializedTechnology
Nessun commento:
Posta un commento